16 completed, 6 terminated, 4 active not recruiting, 4 recruiting. 32 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 32 | Completed 16, Terminated 6, Active not recruiting 4, Recruiting 4, Unknown 2 |
| Phase 2 | 9 | Completed 4, Terminated 3, Active not recruiting 1, Unknown 1 |
Follow Prostate Adenocarcinoma: new trials by email Literature Review of Prostate Adenocarcinoma trials Research Report on Prostate Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer Copper 61-PSMA PET/CT - Prostate Adenocarcinoma | Phase 1 | Recruiting | Hoag Memorial Hospital Presbyterian | 8 | 2024-10-14 | 2024-12-16 |
| Enzalutamide Implants (Enolen) in Patients With Prostate Cancer enzalutamide - Prostate Adenocarcinoma | Phase 1 | Recruiting | Alessa Therapeutics Inc. | 45 | 2024-06-21 | 2026-08-11 |
| PSMA PET Response Guided SabR in High Risk Pca 68-Ga PSMA11 - Prostate Adenocarcinoma | Phase 1 | Recruiting | University of Texas Southwestern Medical Center | 20 | 2024-03-07 | 2026-04-14 |
| Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy - Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma | Phase 1 | Active not recruiting | Emory University | 6 | 2023-11-29 | 2025-12-09 |
| Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors BL-B01D1 - Non Small Cell Lung Cancer, Esophageal Cancer | Phase 1 | Recruiting | SystImmune Inc. | 540 | 2023-08-08 | 2026-09-21 |
| A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients Relugolix Pill, Ritonavir, Itraconazole - Prostate Cancer, Prostate Cancer Metastatic | Phase 1 | Terminated | University of Chicago | 60 | 2023-02-13 | 2024-09-19 |
| Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log - Prostate Cancer, Prostate Adenocarcinoma | Phase 1 | Terminated | University of Chicago | 50 | 2023-01-24 | 2025-10-03 |
| Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer bicalutamide, Stereotactic body radiation therapy - Prostate Adenocarcinoma | Phase 1 | Active not recruiting | Alessa Therapeutics Inc. | 20 | 2021-12-07 | 2026-02-27 |
| Fluorescent Imaging of Nerves With Illuminare-1 During Surgery Illuminare-1, Karl Storz D-Light C photodynamic diagnostic (PDD) - Prostate Adenocarcinoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 41 | 2021-10-04 | 2025-09-16 |
| An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer Fluorine F 18 rhPSMA-7.3, Magnetic Resonance Imaging, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 29 | 2021-08-04 | 2024-10-23 |
| Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer External beam radiation therapy, High-dose-rate brachytherapy, Goserelin 10.8 mg - Prostate Adenocarcinoma, Radiation Toxicity | Phase 1 / Phase 2 | Active not recruiting | German Oncology Center, Cyprus | 40 | 2021-08-01 | 2026-09-17 |
| Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) Hypofractionated Radiation Therapy - Prostate Cancer, Prostate Adenocarcinoma | Phase 1 | Active not recruiting | University of Maryland, Baltimore | 18 | 2020-11-19 | 2026-11-05 |
| A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer Bicalutamide implant - Prostate Adenocarcinoma, Lower Urinary Tract Symptoms | Phase 1 | Completed | Alessa Therapeutics Inc. | 17 | 2020-10-11 | 2024-06-24 |
| Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer Epidiolex Oral Liquid Product - Prostate Cancer Recurrent, Prostate Cancer | Phase 1 | Completed | Zin W Myint | 21 | 2020-08-03 | 2025-03-05 |
| Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring Gonadotrophin Releasing Hormone, Intensity-Modulated Radiation Therapy, Niraparib - Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8 | Phase 1 / Phase 2 | Completed | NRG Oncology | 22 | 2019-10-08 | 2026-07-10 |
| A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer Talazoparib, Temozolomide - Prostate Cancer, Prostate Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 16 | 2019-07-11 | 2026-08-24 |
| 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Lutetium Lu 177-PSMA-617, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | University of California, San Francisco | 43 | 2019-05-10 | 2025-02-25 |
| Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer Entinostat, Enzalutamide - Prostate Adenocarcinoma | Phase 1 | Terminated | George Washington University | 6 | 2019-05-01 | 2021-08-02 |
| Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer Daratumumab, FMS Inhibitor JNJ-40346527, Radical Prostatectomy - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 33 | 2017-06-07 | 2024-05-03 |
| A Study Evaluating MM-310 in Patients With Solid Tumors MM-310 - Solid Tumors, Urothelial Carcinoma | Phase 1 | Unknown | Merrimack Pharmaceuticals | 34 | 2017-02-22 | 2018-02-27 |
Showing 20 of 32. Sign in to see all of them.
Prostatic Neoplasms (17) · Carcinoma, Non-Small-Cell Lung (4) · Breast Neoplasms (2) · Endometrial Neoplasms (2) · Melanoma (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms, Male (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Glioma (1) · Lower Urinary Tract Symptoms (1)
Neoplasms by Site (21) · Neoplasms (20) · Genital Diseases (19) · Urogenital Diseases (19) · Urogenital Neoplasms (19) · Genital Diseases, Male (17) · Genital Neoplasms, Male (17) · Male Urogenital Diseases (17) · Prostatic Diseases (17) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Breast Diseases (4) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Lung Diseases (4)
Magnetic Resonance Spectroscopy (3) · Goserelin (2) · Radiosurgery (2) · X-Rays (2) · bicalutamide (2) · enzalutamide (2) · pembrolizumab (2) · Abiraterone Acetate (1) · Androgen Antagonists (1) · BCT-100 (1) · Calcitriol (1) · Carboplatin (1) · Chlorotoxin (1) · Congresses as Topic (1) · Gonadotropin-Releasing Hormone (1)
Alessa Therapeutics Inc. (3) · M.D. Anderson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (2) · NRG Oncology (2) · National Cancer Institute (NCI) (2) · University of Chicago (2) · Bio-Cancer Treatment International Limited (1) · Emory University (1) · George Washington University (1) · German Oncology Center, Cyprus (1) · Hoag Memorial Hospital Presbyterian (1) · Institut Cancerologie de l'Ouest (1) · Massachusetts General Hospital (1) · Merrimack Pharmaceuticals (1) · Roswell Park Cancer Institute (1)
United States (29) · Canada (3) · France (2) · Australia (1) · Cyprus (1) · Italy (1) · Japan (1) · New Zealand (1) · Spain (1) · Switzerland (1)
Alberto Bessudo, MD (1) · Andrew A Loblaw (1) · Christopher Logothetis (1) · Dana Rathkopf (1) · David M Schuster, MD, FACR (1) · Deborah Citrin, MD (1) · Devaki Shilpa S Surasi (1) · Douglas G McNeel, MD PhD (1) · Iosif Strouthos, MD PhD (1) · Jay-Jiguang Zhu, MD (1) · Jeffrey Raizer, M.D. (1) · Jianquig Lin, MD (1) · Jimmy Zhao, MD, PhD (1) · John Fiveash, MD (1) · Karen Autio, MD (1)
PMID 20818327, PMID 23553848, PMID 29776373, PMID 29876010, PMID 30700328, PMID 31400383, PMID 31515154, PMID 33885704, PMID 35277461, PMID 37419394, PMID 37619656, PMID 37922930, PMID 38407630, PMID 40601345, PMID 40906325, PMID 41363974, PMID 41378786
P30CA016672 (3), U10CA180868 (2), N01CM00039 (1), N01CM62202 (1), P30CA008748 (1), P30CA016056 (1), P30CA138292 (1), R01CA229354 (1), U01CA062461 (1), U01CA062491 (1), U01CA069856 (1), U10CA021661 (1), ZIABC010850 (1), ZIABC011081 (1), ZIABC011552 (1)